TREATMENT AND PROPHYLAXIS - REVIEW

Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential

Sajad Rashidi1 · Celia Fernández-Rubio2 · Reza Mansourì3 · Mohammad Ali-Hassanzadeh4 · Esmaeel Ghani5 · Mohammadreza Karimazar1 · Raúl Manzano-Román6 · Paul Nguewa2

Received: 13 September 2021 / Accepted: 29 November 2021 / Published online: 6 January 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
The current drug treatments against protozoan parasitic diseases including Chagas, malaria, leishmaniasis, and toxoplasmosis represent good examples of drug resistance mechanisms and have shown diverse side effects. Therefore, the identification of novel therapeutic strategies and drug compounds against such life-threatening diseases is urgent. According to the successful usage of selenium (Se) compounds-based therapy against some diseases, this therapeutic strategy has been recently further underlined against these parasitic diseases by targeting different parasite’s essential pathways. On the other hand, due to the important functions played by parasite selenoproteins in their biology (such as modulating the host immune response), they can be also considered as a novel therapeutic strategy by designing specific inhibitors against these important proteins. In addition, the immunomodulatory potentiality of these compounds to trigger T helper type 1 (Th1) cells and cytokine-mediated immune response for the substantial induction of proinflammatory cytokines, thus, Se, selenoproteins, and parasite selenoproteins could be further investigated to find possible vaccine antigens. Herein, we collect and present the results of some studies regarding Se-based therapy against protozoan parasitic diseases and highlight relevant information and some viewpoints that might be insightful to advance toward more effective studies in the future.

Keywords Selenium · Se-nanoparticles · Se supplementation · Therapy · Protozoan parasitic diseases

Introduction

Drug efficacy against protozoan parasites is variable among species and genus and some of them are only active in the acute phase of the infection with potential side effects of the used compounds. Accordingly, the programs to
control parasitic diseases such as leishmaniasis, toxoplasmosis, malaria, and Chagas are facing huge challenges due to ineffective therapies and drug resistance (Andrews et al. 2014). Therefore, the threat of such diseases remains a priority of public and global health. All these issues prompted scientists to continuously look for novel therapeutic drugs, and selenium (Se)-based/containing compounds (selenocompounds) have shown promising results in this sense for many infectious and parasitic diseases (Brindha 2021; Chuai et al. 2021; Da Silva et al. 2014; Kieliszek and Lipinski 2020; Letavayová et al. 2006; Steinbrenner et al. 2015). Se trace element plays important role in human health, due to its anti-inflammatory, pro-immune, and antioxidant properties (Bai et al. 2017; Hariharan and Dharmaraj 2020). Se exerts its biological effects mostly through its incorporation into selenoproteins, which have the inclusion of at least one selenocysteine residue in its sequence driving Se toward its biological functions and also decreases cytotoxicity effects (Bartolini et al. 2017). Se atom has unique physicochemical properties leading for example to selenoproteins show higher catalytic efficiency or higher nucleophilicity which have significant biological relevance (Arnér 2010, 2020). The biological properties of Se are important once incorporated into selenoproteins. Most selenoproteins are involved in redox systems with the potentiality to react with molecular oxygen and thiols to develop crucial homeostatic processes in different cells and tissues but also with signaling pathways, accordingly, selenoproteins functions are affected by the balanced cellular level of Se/or Se-related biomolecules (selenocompounds). Thus, these compounds may influence the redox homeostasis and cell signaling potentially impacting regulatory elements (Bartolini et al. 2017; Kurokawa and Berry 2013). Selenocompounds known as Se-containing molecules are described in various therapeutic strategies. Se dioxide and selenites in the form of sodium selenite have been suggested as the most studied inorganic selenocompounds. Other compounds including methylseleninic acid, isoselenaolanes, seleneoureas, diselenides, selenocarbonyl derivatives, selenocyanates and iso-selenocyanates, selenoxides, selenazoles, and selenediazoles, as well as Se-containing amino acids (selenocysteine, selenocystine, selenomethionine and methylselenocysteine), have been also considered organic selenocompounds which could be used in Se therapy/supplementation (Bartolini et al. 2017).

The host immune response might be affected by Se and selenoproteins (Se supplementation) on the immune cells (Fig. 1) (Bae and Kim 2020; Nelson et al. 2016; Sperk et al. 2020; Sun et al. 2017; Xia et al. 2021) or selenoproteins expressed by immune cells (Huang et al. 2012). There are several studies demonstrating that sufficient Se levels even achieved by Se supplementation regulate or decrease the level of inflammatory cytokines (Daeian et al. 2014; Kudva et al. 2015; Zhou et al. 2014). For instance, an adequate level of Se contributes to optimal levels of interleukin 6 (IL-6), both in health and disease. The increased expression of IL-6 in SARS-CoV-2 infected cells revealed a potential link between decreased selenoprotein expression and

Fig. 1 The regulatory effects of Se and selenoproteins on the immune cells

© Springer
COVID-19-associated inflammation (Zhang et al. 2020). In addition, selenocompounds/selenoproteins have been found to be inhibitors of the nuclear factor-kappa β (NF-κβ), as the coordinator of inflammatory cytokines (such as IL-6) activation (Zhang et al. 2020). This information highlights that Se adequacy prevents excessive cytokine activation in infectious and inflammatory conditions. Contrarily, Se deficiency led to a reduction in selenoproteins gene expression and further affected cytokines levels (low expression levels of IL-2, IL-1β, IL-6, interferon alpha (IFN-α), IL-17, and high expression levels of IL-8, IL-10, IFN-γ, IFN-β, and tumor necrosis factor alpha (TNF-α) in the Se-deficient animal models compared to the control groups) (Khoso et al. 2019).

Furthermore, Se, selenocompounds, and selenoproteins seem to modulate the immune response and consequently increase host defense against oxidative stress (antioxidant defense, redox signaling, and redox homeostasis) (Da Silva et al. 2014; Guillin et al. 2019). It is well known that the ability of different intracellular pathogens to encounter host-derived reactive species is remarkably related to the potential capacity of their antioxidant networks at the beginning of invasion, which consequently influence the balance toward pathogens survival, proliferation, and virulence over redox-dependent control of infection (Mesías et al. 2019; Piacenza et al. 2019). During parasitic infection, the immune system can generate oxidant molecules as defense mechanism that may lead to an oxidative stress status if these are not sufficiently counteracted by the antioxidant system (van de Crommenacker et al. 2012). Therefore, the selenoproteins are vital enzymes involved in overcoming the oxidative stress induced through the excessive generation of reactive oxygen species (ROS) (Avery and Hoffmann 2018).

Accordingly, Se, selenocompounds, and selenoproteins deficiency may lead to an unbalanced immune system and subsequent pathogenesis progression in the host (Amankwah and Han 2018; Khatiwada and Subedi 2021; Yazdi et al. 2015; Zhang et al. 2021). Thus, the supplementation or treatment with these compounds might be beneficial for the control or elimination of several pathologies such as protozoan parasitic infectious diseases.

### Selenocompounds modulating the host immune system during protozoan parasitic infections

It has been shown that Se and selenocompounds significantly improve the efficiency of the host immune system’s function (innate and adaptive) against pathogens (Parnham 2011; Yazdi et al. 2015), including protozoan parasites. It seems that the possible mechanisms of action of such compounds in vivo include their anti-apoptotic activity and their protection against cellular damage during intracellular protozoan parasitic infections through the alteration of lipid peroxidation and endogenous antioxidant enzymes (Alkhuwari et al. 2020; Sheneni et al. 2018).

In Chagas disease patients, low Se levels seemed to be a biological marker for the pathology and was reported to be related to the progression of *Trypanosoma cruzi* infection (Rivera et al. 2002). On the other hand, Se supplementation has been suggested as a potential therapeutic option to modulate the inflammatory, immunological, and antioxidant responses involved in cardiac and intestinal disorders caused by this pathogen (do Brasil et al. 2014; Gomez et al. 2002; Jelicks et al. 2011). In addition, since the titer of anti-*T. cruzi* immunoglobulin G (IgG) is directly correlated with the parasitic load, Se derivatives have recently demonstrated their effects as potential anti-chagasic agents, by decreasing the levels of IgG detected in serum from infected mice during the acute phase (Martín-Escolano et al. 2021a).

Se deficiency induced lower expressions of IL-2 and IL-4 which might contribute to the severity of the parasitic diseases such as that caused by *Cryptosporidium parvum* (Wang et al. 2009). Moreover, it had been speculated that the enhancement of the immune response by non-toxic dosage Se supplementation may also play a role on the inhibition of *C. parvum* infection in the murine model (Huang and Yang 2002).

Interestingly, in acute experimental toxoplasmosis, sodium selenite and diphenyl diselenide may decrease protein oxidation and lipid peroxidation, facilitating a beneficial immunological balance between the production of pro- and anti-inflammatory cytokines. Thus, the administration of organic and inorganic Se derivatives in combination with the common chemotherapy against toxoplasmosis reduced the exacerbated immune response (Barbosa et al. 2014). Currently, the use of nanotechnology and nanoparticles (NPs) has improved the therapeutic strategies in different pathologies including parasitic diseases (Barazesh et al. 2018; Kirtane et al. 2021; Nafari et al. 2020). The large surface-volume ratio of NPs facilitates a number of interactions with biological molecules and pathogens, and the easy penetration of those NPs into cells compare to other particles highly suggests the application of these formulations (Khan et al. 2019). SeNPs have also demonstrated effects against murine toxoplasmosis during both, therapeutic and prophylactic treatment by increasing mRNA levels of *TNF-α, IL-12, IL-10, IFN-γ, and inducible nitric oxide synthase (iNOS)* gene levels (Keyhani et al. 2020a; Keyhani et al. 2020b).

Evidences have shown decreased levels of Se in sera of patients with cutaneous and canine leishmaniasis (Souza et al. 2014; Taghipour et al. 2021). Since this trace element exerts a major regulatory function in the immune system, and host immune responses against leishmaniasis, its level alterations can be associated with the clinical symptoms of
patients with different forms of leishmaniasis (Souza et al. 2014; Taghipour et al. 2021). For the treatment of cutaneous leishmaniasis, the combination of Se with glucantime and anfotericin B has demonstrated a higher activity than each drug alone mainly by increasing IL-12 and decreasing IL-10 gene expression (Mostafavi et al. 2019a; Mostafavi et al. 2019b).

SeNPs have shown higher anti-parasitic, anti-oxidant, and anti-inflammatory effects than free sodium selenite against murine coccidiosis. This activity occurs through the regulation of the expression of pro-inflammatory cytokines (IL-1β, IL-6, IFN-γ, and TNF-α) and protective glycoproteins genes in the jejunum (Alkhudhayri et al. 2018). Similarly, SeNPs were able to reverse the imbalance in the antioxidant status and to reduce apoptosis of jejunal cells during Eimeria infection (Alkhudhayri et al. 2020).

In overall, Se and selenocompounds significantly improve the host immune system’s responses toward the elimination of the parasitic infections. Nevertheless, it has been shown in animal models infected with T. cruzi that the treatment with selenocompounds (sodium selenite) induced a serologic decrease of pro-inflammatory cytokines (IL-12, TNF, and IFN) and a reduction of B-lymphocytes in splenic cells (de Freitas et al. 2018). Therefore, it would be interesting to understand the link between the host immunological status and the use of Se derivatives/selenocompounds for the treatment of parasitic diseases especially under concrete physiological conditions.

Selenocompounds/Se derivatives targeting protozoan proteins involved in vital biological pathways

Besides their capability to regulate the immune responses during parasitic infections, Se/selenocompounds derivatives have also the ability to directly target such pathogens (Keyhani et al. 2020b; Shakibaie et al. 2020). One of the Se derivative’s mechanisms of action seems to be the alteration of pathways allowing the parasites to overcome the oxidative stress. Se supplementation through sodium selenite revealed an anti-coccidian effect of Se in vitro through the formation of free radicals, since this effect was reversed by the addition of free-radical scavengers to the cell culture. This statement was reinforced in vivo supporting an enhanced immune response produced by Se supplementation in mice (Huang and Yang 2002). Based on the low activity of the enzymes involved in antioxidant pathway in C. parvum oocysts, the effect was likely caused by free-radical production.

New organo-Se compounds bearing the sulfonamide moiety have displayed leishmanicidal activities by inhibiting the β-isoinform of carbonic anhydrase from Leishmania donovani chagasi, which is considered a specific and promising therapeutic target against these pathogens since the host cells lack such an isoform (Al-Tamimi et al. 2019; Cabrera et al. 2021). Similarly, trypanothione reductase (TryR), catalyzing the reduction of trypanothione disulfide to trypanothione in trypanosomatids, remains a promising target due to its important role in the protection against ROS and its absence in vertebrates. Based on the analogy of sulfur and Se, diselenide and selenocyanate derivatives have been proposed as new TryR inhibitors (Baguedano et al. 2016; Etxebeste-Mitxeltorena et al. 2020; Garnica et al. 2020). Among selenourea derivatives of diselenides series, 1,1’-(4,4´-Diselanediylbis(4,1-phenylene))bis(3-hexylselenourea) demonstrated an inhibitory activity of L. infantum TryR (Díaz et al. 2019). Furthermore, the inhibition of Fe superoxide dismutase (Fe-SOD) has been suggested as an additional mechanism of action of these compounds on parasites in vitro (Etxebeste-Mitxeltorena et al. 2020; Martín-Escolano et al. 2021a; Mosolygó et al. 2019).

SeNPs have evidenced apoptotic effect against Leishmania promastigotes by increasing mRNA levels of metacaspase (Mostafavi et al. 2019a, 2019b) and by DNA fragmentation (Beheshhti et al. 2013), the most important alterations that occur in programmed cell death (Raina and Kaur 2012; Zhang et al. 2005). Regarding Giardia, the lytic activity of SeNPs against cysts was found to be similar to that of metronidazole (Malekifard et al. 2020). Among other pathways, metronidazole causes DNA fragmentation and consequently, trophozoite death (Gardner and Hill 2001). Thus, this mechanism of action (DNA fragmentation) might be responsible for the death of Giardia cysts in SeNPs-based therapies. However, additional studies will be useful to clarify the activity of selenocompounds and derivatives including SeNPs against intestinal protozoan.

Furthermore, parasite death has been observed using Se derivatives that lead to mitochondrial membrane depolarization and bioenergetic collapse in T. cruzi and consequently, the reduction of DNA replication and RNA transcription rates (Martín-Escolano et al. 2021a; Martín-Escolano et al. 2021b). Moreover, molecules involved in cell cycle such as proliferating cell nuclear antigen (PCNA), mini-chromosome maintenance complex (MCM4), or Topoisomerase-II (TOP2) have been described as targets of Se derivatives compounds in Leishmania parasites (Fernández-Rubio et al. 2015; Fernández-Rubio et al. 2019).

Other vital metabolic pathways may be altered by selenocompounds. Diselenides derivatives have proven antiparasitic effect against African trypanosomes affecting the highly dependent parasite glucose metabolism (Franco et al. 2017). Furthermore, the ergosterol biosynthesis pathway has been also reported as a molecular target for T. cruzi, Se-containing analogues of WC-9 might act as parasite squalene synthase inhibitors (Chao et al. 2017). All these current data suggest that further investigations are needed to better understand
the mechanisms of action of selenocompounds and derivatives during host cell protozoan parasitic infections.

The parasitic selenoproteome: a promising therapeutic target and potential source for vaccine antigens

It is well known that pathogenic trypanosomatids have conserved the machinery responsible for selenocysteine biosynthesis and its incorporation in selenoproteins (Manhas et al. 2016). In addition, only three selenoproteins containing a redox center selenocysteine-based have been reported in trypanosomatids (da Silva et al. 2020). However, regarding the African Trypanosoma, it seems that those selenoproteins were not required for infectivity and acute infection progression in mice, and null-mutants showed similar sensitivity to stress conditions and to drugs targeting these enzymes than wild-type strains (Aeby et al. 2009; Bonilla et al. 2016). Moreover, the ablation of enzymes participating in selenoproteins synthesis caused a higher sensitivity to endoplasmic reticulum stressors, one of those selenoproteins containing selenocysteine in its redox domain demonstrated to be dispensable for T. brucei (da Silva et al. 2020). Accordingly, since most selenoproteins are important redox enzymes containing a catalytic selenocysteine residue, the selenoproteome of the protozoan parasites could link with critical functions and vital mechanisms in these parasites (Lobanov et al. 2006b). In addition, further studies on parasites’ selenoproteome might shed some light on the biology of these proteins (Lobanov et al. 2006a; Lobanov et al. 2006b; Röseler et al. 2012).

On the other hand, selenocompounds and selenoproteins might improve the immune system, and the parasite’s adaptation to these compounds could then take place by expressing specific proteins (such as parasite’s selenoproteins) in their structures/proteome or, by adapting the uptake of Se from the aforementioned compounds to the parasite selenoproteins synthesis pathway (Kalantar et al. 2021; Rashidi et al. 2020a). Furthermore, high levels of selenoproteins have been related to the impairment of immune system functions, so it has been postulated that the overexpression and release of selenoproteins by some protozoan parasites such as Leishmania might be involved in suppression of the host innate immunity (Rashidi et al. 2020a). Consequently, the expression of different proteins including selenoproteins in protozoan parasites proteome might be considered a defensive strategy against Se-based compounds. All of the aforementioned information further highlights the crucial and potential biological function of parasites’ selenoproteome, which could be aimed as promising therapeutic targets in the treatment of parasitic diseases. The analysis of the selenoproteome expression in parasites exposed to selenocompounds remains an interesting challenge.

Methods for the identification and expression of selenoproteins can increase our information concerning selenoproteins functions. The targeting of reactive selenocysteine residues with electrophilic probes, along with progression in computational and experimental Se detection in proteomic samples, has recently developed the scope of questions significantly that can be addressed in selenoproteomics (Peeler and Weerapana 2019). Consequently, proteomic approaches might be appropriate tools for the identification of selenoproteins involved in parasite pathways facilitating the modification of the host immune responses (Bennett and Robinson 2021; Herbison et al. 2019; Sperk et al. 2020). Accordingly, a few studies based-proteomic and genomic techniques have identified the expression of several selenoproteins and key derivatives in the proteome of some protozoan parasites (Lobanov et al. 2006a, 2006b; Novoselov et al. 2007; Rashidi et al. 2020b; Röseler et al. 2012). Bioinformatics tools have also facilitated the identification of various selenoproteins through selenoproteins genome finding in different organisms (Fig. 1) (Santesmasses et al. 2020).

Thioredoxin glutathione reductase (TGR) is a parasite selenoprotein required for the survival of schistosomes in the mammalian host. Consequently, selenoproteins inhibitors were recently designed and applied against schistosomiasis. Interestingly, such inhibitors were active against all important species and development stages and immature worms. It seems that some of these inhibitors may induce a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in TGR, leading to the generation of superoxide and hydrogen peroxide (Lyu et al. 2020). Altogether, experimental data confirm that by targeting or inhibiting selenoproteins, novel effective therapeutic strategy may be developed against protozoan parasites (Andrade and Reed 2015). Most of the selenoproteins are responsible for the protection against oxidative damage through redox activities. Moreover, Se-independent homologues of these proteins have been characterized in protozoan parasites (except in C. parvum). For instance, C. parvum parasite completely lacks selenoproteins, but the glutathione peroxidase (with cysteine instead of selenocysteine in its active site) had been described (Kang et al. 2014). So, this enzyme is not inhibited by potassium cyanide, a known selenoprotein inhibitor which exerts its activity by releasing the Se atom from the enzyme active site.

Auranofin, the first oral gold salt approved by the United States Food and Drug Administration (FDA) to treat rheumatoid arthritis, has demonstrated anti-parasitic activity thanks to its monovalent gold molecule inhibiting parasitic enzymes involved in the control of the redox metabolism (Andrade and Reed 2015; Angelucci et al. 2009; Ilari et al. 2012). By analyzing the crystal structure of Schistosoma
mansoni thioredoxin-glutathione reductase, Agelucci et al. suggested a role of selenocysteine in gold transference from the compound to the cysteine couple of the TGR from the parasite. In fact, the gold-compound was less active against the enzyme from the same family lacking the selenocysteine in its active site (Angelucci et al. 2009). Since, selenoproteins have been described in several protozoan parasites (Lobanov et al. 2006b), the auranofin antiparasitic activity may be related to its activity as selective selenoproteins inhibitor. However, this compound also showed to be active against the L. infantum thrypanothione reductase (TR), which lacks selenocysteine motif in its active site by a mechanisms involving the cysteine residues of the protein and trypanothione binding site of the protein instead selenoproteins inhibitor (Ilari et al. 2012). Similarly, C. parvum that lacks selenoproteins has been shown to be sensitive to auranofin (Debnath et al. 2013). Auranofin-treated Entamoeba histolytica trophozoites were shown to be more sensitive to oxidative stress. Additional assays demonstrated that the thioredoxin lacking selenocysteine from these parasites was also the target of this gold-compound (Andrade and Reed 2015; Parsonage et al. 2016). Since auranofin showed to be more active against selenocysteine-containing proteins, further experiments are needed to determine the role of Se in the mechanism action of compounds targeting selenoproteins in protozoan parasites.

There is not enough information regarding the development of selenoproteins as vaccine candidates against parasitic diseases. However, due to the immunomodulatory potentiality of these compounds to trigger T helper type 1 (Th1) cells and cytokine-mediated immune response for substantial induction of proinflammatory cytokines (Dharmalingam et al. 2021), Se, selenoproteins, and parasite selenoproteins could be further investigated to find possible vaccine antigens in the parasitology field. The immunogenic nature of selenoproteins from protozoan parasites was explored by using a DNA vaccine encoding a Se-dependent glutathione reductase (GR) from Toxoplasma gondii. In the immunized mice, the humoral response showed significant higher titers of total IgG, IgA, and IgM, and the provoking cellular immune response was confirmed by an increment of IFN-γ, IL-4, IL-17, and transforming growth factor beta 1 (TGF-β1) cytokines compared with the control group. These results suggest that TgGR could induce humoral and cellular protective immune responses and an acceptable level of resistance against toxoplasmosis (Hassan et al. 2014). Moreover, it has been demonstrated that a dietary supplementation with Se compounds may potentially improve the immunogenicity and protective efficacy of some types of vaccines used against viral infections marked by the production of higher levels of specific antibodies and lower viral infection levels in the Se compounds-treated groups (Shojadoost et al. 2020). Therefore, such strategy might be also evaluated in vaccination strategies against parasitic infections.
The Se/selenocompounds-based protective and preventive therapy

The protective role of Se has been well described in cancers and antioxidant activity of this compound and its effects on cellular redox status has been suggested as the most related strategy (Björnstedt and Fernandes 2010; Kuršvietienė et al. 2020; S Darvesh and Bishayee 2010). In addition, Se-based protective and preventive therapy has shown satisfactory results in other pathologies such as euthyroid nodular goiter (Turun and Turksoy 2021), acute ischemic stroke (Mirończuk et al. 2021), or infectious diseases caused by bacteria (Kim et al. 2012), virus (Kieliszek and Lipinski 2020), and parasites (Hooper et al. 2014; Volpato et al. 2018).

Se deficiency can promote mutations, propagation, and virulence of viruses especially RNA viruses. Se might be beneficial through restoration of host antioxidant capacity and critical lymphocyte counts for the cytotoxic immune response, decrease of apoptosis, endothelial cell damages and platelet aggregation, and finally improvement of the clinical symptoms (Hiffler and Rakotoambinina 2020; Notz et al. 2021). Recent data indicate that sodium selenite probably induced an efficient protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19). This chemical compound can oxidize thiol groups in the virus protein disulfide isomerase (PDI) leading to unsuccessful virus penetration into the non-infected cell membrane as well as infectivity restriction (Kieliszek and Lipinski 2020). Thus, since the Se supplementation-based protective therapy was found effective against intracellular pathogens such as viruses, its potential for preventing intracellular protozoan parasites to reduce the risk or modulate resistance to infectious diseases could be also evaluated.

It was shown that Se provided by Se supplementation can increase the function of cytotoxic effector cells and may also be important for maintaining T cell maturation and functions, as well as for T cell-dependent antibody production (Bae and Kim 2020). The initial immune status of the host (before infection) is critical for the development of clinical manifestations during parasitic infectious disease and Se-supplementation in the diet may be essential in maintaining the immune response. For instance, it has been reported a decrease of Th1 and Th2 cytokines in mice fed with Se deficient diet during C. parvum infection compared to their levels in animals feed with adequate amounts of this essential element (Wang et al. 2009). Mineral compounds subcutaneously administered including Se increased the number of leukocytes and immunoglobulins serum levels in new-born lambs and heifers, inducing protection against coccidiosis and giardiasis (Cazarotto et al. 2018; Volpato et al. 2018). Similarly, sufficient Se supply in mice caused a substantial lowering of fecal shedding of oocysts from mice, while Se-deficient diet was associated with an accelerated expulsion of oocysts, presumably due to an impaired development of parasites in the jejunum (Dkhil et al. 2014).

Se-based NPs have also demonstrated preventive effects on the protozoan parasitic diseases. The number of tachyzoites was significantly lower in mice which had orally received SeNPs before being infected by Toxoplasma than in the control group. The expression levels of IFN-γ, TNF-α, IL-12, IL-10, and iNOS considerably increased in the treated group, illustrating the improvement of the immune system, especially the cellular immunity, which caused resistance to the infection (Shakibaie et al. 2020). On the other hand, Se supplementation had been suggested in the prevention of right ventricle chamber dilatation and reversion of T. cruzi-induced acute and chronic cardiomyopathy in mice (de Souza et al. 2010).

Se, Se derivatives, and selenocompounds-based therapy against protozoan parasitic infections

In agreement with the aforementioned information, many in vivo and in vitro studies have attempted to develop Se, Se derivatives, and selenocompounds-based therapy strategy against different protozoan parasitic diseases. Table 1 presents the potential treatments against parasitic protozoan infections with these compounds, highlighting their role on both, the host and the parasite.

Interestingly, selenocompounds are also involved in the regulation of exacerbated immune responses and chronic inflammation (Huang et al. 2012). Since both, the deficiency and high Se supplementation, can cause physiologic alterations such as immune-related disturbances in the human body, the control of the therapeutic doses remains crucial. Thus, the adverse effects of long-term selenocompounds-based therapy/Se supplementation are an important issue that should be undertaken in therapeutic strategies and clinical trials by these compounds. In fact, Se has a narrow therapeutic window and its toxicity margins are critical (Khurana et al. 2019). Therefore, although the results of most of these in vivo and in vitro studies (Table 1) have been successfully reported as an alternative strategy instead of the current drugs, their toxicity should not be negligible. More investigations are needed to determine the therapeutic window allowing the prevention of protozoan parasitic diseases without exhibiting toxicity in the host. New strategies could involve the use of nanocarriers, such as NPs, to increase the selenocompounds solubility, permeability, bioavailability, and consequently might be indirectly helpful.
Table 1 In vitro and in vivo effects of Se/selenocompounds-based therapy against protozoan parasites

| Protozoan parasites | Se compounds                                                                 | Efficacy                                                                                     | Possible mechanism of action                                                                 | References                                      |
|---------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------------------|
| *L. tropica*        | Niosomal combination of Se coupled with Amphotericin B, and Glucantime       | Leishmanicida (promastigote and amastigote)                                                  | Decreasing the levels of IL-10 and increasing IL-12 (as Th1 activator)                       | (Mostafavi et al. 2019a, 2019b)                  |
| *L. major*          | Methylseleno-Imidocarbanates                                                  |                                                                                             | Inducing nitric oxide production, potent effect on the cell cycle (inducing arrest in G1)   | (Fernández-Rubio et al. 2015)                   |
| *L. major and amazonensis* | Naphthalamide iso sel enocy anate-6 (NISC-6)                              | Leishmanicida (amastigote)                                                                 | Reduced expression of *Leishmania* genes involved in the cell cycle (*TOP2, PCNA, and MCM4*), increase of cells in the G1 phase and reduction of cells in the S phase | (Fernández-Rubio et al. 2019)                   |
| *L. infantum*       | Selenocyanate and diselenide derivatives containing amide moiety            | Leishmanicida (amastigote)                                                                 | Targeting parasite trypanothione reductase                                                    | (Baquedano et al. 2016; Etxebeste-Mitxeltorena et al. 2020) |
|                     | Heteroaryl Selenocyanates and Diselenides                                   |                                                                                             |                                                                                            | (Díaz et al. 2019)                              |
|                     | Selenourea derivatives of Diselenides                                       |                                                                                             |                                                                                            | (Alcolea et al. 2021)                           |
|                     | 3,5-Dimethyl-4-isoxazoyl selenocyanate (a compound with good intestinal permeability) |                                                                                             | Reducing parasite load in liver (99.2%), spleen (91.7%) and bone marrow (61.4%)              |                                                |
| *L. donovani and infantum* | Organoselenium bearing sulfonamide moiety                                 | Leishmanicida (amastigote)                                                                 | Parasite Carbonic Anhydrase inhibitors                                                        | (Al-Tamimi et al. 2019)                         |
|                     | Organic Se compounds                                                        |                                                                                             |                                                                                            | (Cabrera et al. 2021)                           |
| *L. infantum and braziliensis* | Se                                                                               | Leishmanicida (promastigote and amastigote)                                                | Inhibiting Fe-SOD                                                                             | (Martín-Montes et al. 2017)                     |
| *L. tropica, major and donovani* | SeNPs                                                                          | Leishmanicida (promastigote and amastigote)                                                | Inducing apoptosis in promastigotes                                                           | (Beheshiti et al. 2013; Mahmoudvand et al. 2014; Soflaei et al. 2014) |
| Protozoan parasites | Se compounds | Efficacy | Possible mechanism of action | References |
|---------------------|--------------|----------|-----------------------------|------------|
|                      |              | In vitro | In vivo                     |            |
| **T. gondii**        | Se-containing analogues of WC-9 | Activity against tachyzoites | Reducing IFN-γ and increasing IL-10 (preventing excessive tissue damage) | (Chao et al. 2017) |
|                      | Sulfamethoxazole/Trimethoprim supplemented with diphenyl diselenide and sodium selenite | | Protective mechanism through the balance between pro- and anti-inflammatory cytokines | (Barbosa et al. 2014) |
|                      | Diphenyl diselenide | Decreasing thiobarbituric acid reactive species (TBARS) levels in infected mice and increasing the Glutathione S transferase (GST) activity in the brain | Protective action as antioxidant | (Machado et al. 2016) |
|                      | SeNPs | Increasing mRNA levels of inflammatory cytokines (TNF-α, IL-12, IL-10, IFN-γ) and iNOS, decreasing parasite load in infected tissues and mortality rate (up to 100%) | | (Keyhani et al. 2020b; Shakibaie et al. 2020) |
| **Giardia deodenalis** | | Same effect and more cytotoxicity compared to Metronidazole in killing of cysts | | (Malekifard et al. 2020) |
| **Eimeria papillata** | | Decreasing the numbers of meronts, gamonts, and developing oocysts, regulating the expression of pro-inflammatory cytokines (IL-1β, IL-6, IFN-γ and TNF-α) and protective glycoproteins genes in the jejunum | Reversing the disturbance of the redox status in infected cells (antioxidant property), reducing the Bax and caspase-3 expression (anti-apoptotic property) | (Alkhudhayri et al. 2020; Alkhudhayri et al. 2018) |
| **T. cruzi**         | Selenocompounds (derivative 26), Selenocyanate and Diselenide derivatives | Trypanocidal | Mitochondrial membrane depolarization, inhibition of nucleic acid levels, Fe-SOD enzyme inhibition (cell death induction by bioenergetics collapse) | (Martín-Escolano et al. 2021a; Martín-Escolano et al. 2021b) |
|                      | Selenocyanate derivatives (analouges of WC-9) | Trypanocidal | Inhibitor of parasite squalene synthase | (Chao et al. 2019) |
|                      | Selenides-1,2,3-triazoles | A possible effective compound (further in vitro and in vivo studies are needed) | | (Brasil et al. 2020) |
in decreasing the side effects/toxicity (Khan et al. 2019; Yetisgin et al. 2020). Table 1 also confirms SeNPs potentials in comparison with other compounds. The recently shown hepatoprotective actions and antioxidant properties of plant-based SeNPs and the use of such compounds as an important therapeutic strategy against diabetes, various cancer cells, viral infections, bacterial diseases, and parasitic infections (malaria and leishmaniasis) also highlight the great potential of novel selenocompounds based on NPs for the management of parasitic diseases (Ikram et al. 2021). As a possible larvicidal mechanism of action for plants-based SeNPs in a dose-dependent manner in malaria and leishmaniasis (Suganya et al. 2014), these compounds could denature the special sulfur-containing proteins and phosphorus-containing compounds like DNA and also leads to the denaturation of vital organelles consequently decrease membrane permeability, reduces or disrupt adenosine 5’-triphosphate (ATP) synthesis which finally leads to cell death (Krishnan et al. 2020; Sowndarya et al. 2017). Although further experiments are needed to compare the advantages and side effects/toxicity of plants-based SeNPs in comparison with other forms of SeNPs and other selenocompounds in treatment approaches, the integration of plant-based SeNPs in experimental therapeutic strategies against protozoan parasite can provide more details regarding the therapeutic properties of such compounds.

Besides their toxicity, other factors need to be considered such as the costs and time needed for the synthesis of selenocompounds. Therefore, alternatives to the novo synthesis of selenocompounds should be explored. For example, those compounds synthetized and tested against other pathologies such as cancer are now tested in models mimicking these parasitic diseases (Fernández-Rubio et al. 2019). Currently, another successful approach widely extended is the use of in silico methods to identify and validate both new compounds and therapeutic targets (Peña-Guerrero et al. 2021). As mentioned, these methods have been used to study the selenoproteome of protozoan parasites (Lobanov et al. 2006a, b; Röseler et al. 2012) and the likely organic selenocompounds target (Cabrera et al. 2021). In addition, the complex life cycles of protozoan parasites are key factors to be analyzed during the development of reliable models of study. The characterization of selenoproteins in the infective stage or the effect of selenocompounds on immune response remain difficult since the current in vivo experimental models are not the natural hosts of the pathogens.

It would be interesting to use additional techniques including proteomics and metabolomics to study the role of the selenoproteins in the life cycle of these parasites, the protection against conventional and new treatments, as well as drug resistance. Furthermore, the effects of such compounds depend on the Se chemical form administered. For example, organic selenocompounds do not produce Se accumulation

| Protozoan parasites | Se compounds | Possible mechanism of action | References |
|---------------------|--------------|----------------------------|------------|
| T. brucei | Se+Zinc | Increasing protection against cellular damage | (Sheneni et al. 2018) |
| | Diglycosyl diselenides | Regulating lipid peroxidation and endogenous antioxidant enzymes | (Franco et al. 2017) |
| | Se | Altering glucose metabolism in parasites, interference with the redox homeostasis | (Huang and Yang 2002) |
| C. parvum | Se-compounds reactions with thiols (glutathione) and enhanced levels of superoxide and hydrogen peroxide | Decreasing number of oocysts in feces and a longer survival time in infected mice | (Huang and Yang 2002) |

Table 1 (continued)
in cells, and therefore the oxidative stress caused by Se accumulation can be prevented (Shalini and Bansal 2007). However, when dealing with intracellular parasites, compounds must exert their activities within hosts’ cells, so the accumulation should be assessed. There are in silico methods developed to predict the bioavailability of chemical compounds and to choose the administration route. Further experiments must be performed to analyze the pharmacokinetic features of selenocompounds. Besides the low effectiveness of the current therapy and the lack of proper vaccines, the emergence of drug resistant strains has become a priority for the control and elimination of these diseases. The combination therapy remains a good option since previous results had been successful (Hallett et al. 2004; Lopez-Velez et al. 2010; van Griensven et al. 2010). Therefore, for the treatment of infections caused by protozoan parasites, the administration of selenocompounds in combination with other chemical compounds is a promising strategy and should continue to be explored (Mostafavi et al. 2019a, b).

**Conclusions and future directions**

Many examples demonstrate the re-emergence of protozoan parasitic diseases mainly due to the lack of effective treatments and vaccines but also for the appearance of parasite drug resistance. So, the selective drug discovery is an important task encountering a number of barriers hampering its proper advance to find new anti-parasite compounds impacting both human and animal health in many countries (Guarner 2019; Haldar et al. 2018; Mills 2020). In this sense, selenoproteins and selenocompounds have been poorly studies in protozoan parasites and here we emphasize its usefulness for the modulation of host inflammatory responses, their role as candidates for novel drug therapies against many life-threatening protozoan parasitic diseases.

As previously demonstrated, Se-based therapies appear promising therapeutic strategies to fight against diseases caused by protozoan parasites through the targeting of different essential pathways of the parasite. The identification of the effective targets for these compounds in the parasites proteomes may lead to the improvements of the designed drug’s efficacy and might be further helpful to understand the mechanism of action of Se compounds against parasites. On the other hand, since parasites selenoproteins play vital functions in the biology of the parasites, they can be also considered as novel therapeutic targets to design specific inhibitors against these important proteins. Although the therapeutic aspects of Se, Se-compounds, and selenoproteins have been highlighted, physiological Se levels in patient’s sera or selenoproteins expressed in pathogens might be also suggested as biomarkers and predictors of infection and disease progress.

**Acknowledgements** PN gratefully acknowledges the support provided by Fundación La Caixa (LCF/PR/PR13/11080005) and Fundación Caja Navarra, Gobierno Navarra Salud (12/2017), Fundación Roviralta, Ubesol, Government of Navarre, Laser Ebro, and Inversores Garcilaso de la Vega S.L. and COST actions CA18217 (ENOVAT) and CA18218.

**Declarations**

**Competing interests** The authors declare no competing interests.

**References**

Aeby E, Seidel V, Schneider A (2009) The selenoproteome is dispensable in bloodstream forms of *Trypanosoma brucei*. Mol Biochem Parasitol 168(2):191–193

Al-Tamimi A-MS et al (2019) Discovery of new organoselenium compounds as antileishmanial agents. Bioorg Chem 86:339–345

Alcolea V et al (2021) 5, Dimethyl-4-isoxazoyl selenocyanate as promising agent for the treatment of *Leishmania infantum*-infected mice. Acta Trop 215:105801

Alkudhairy A et al (2020) Antioxidant and anti-apoptotic effects of selenium nanoparticles against murine eimeriosis. An Acad Bras Cienc 92(2):e20191107

Alkudhairy AA, Dkhil MA, Al-Quraishy S (2018) Nanoselenium prevents eimeriosis-induced inflammation and regulates mucin gene expression in mice jejunum. Int J Nanomed 13:1993–2003

Amankwah N, Han Z (2018) Cardiomyopathy secondary to selenium deficiency: a review of clinical cases. Open Nutr J 12(1):74–88

Andrade RM, Reed SL (2015) New drug target in protozoan parasites: the role of thioredoxin reductase. Front Microbiol 6:975

Andrews KT, Fisher G, Skinner-Adams TS (2014) Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist 4(2):95–111

Angelucci F et al (2009) Inhibition of *Schistosoma mansoni* thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284(42):28977–28985

Arnér ES (2010) Selenoproteins—what unique properties can arise with selenocysteine in place of cysteine? Exp Cell Res 316(8):1296–1303

Arnér ES (2020) Common modifications of selenocysteine in selenoproteins. Essays Biochem 64(1):45–53

Avery JC, Hoffmann PR (2018) Selenium, selenoproteins, and immunity. Nutrients 10(9):1203

Bae M, Kim H (2020) The roles of vitamin C, vitamin D, and selenium in the immune system against COVID-19. Molecules 25(22):5346

Bai K, Hong B, He J, Hong Z, Tan R (2017) Preparation and antioxidant properties of selenium nanoparticles-loaded chitosan microspheres. Int J Nanomed 12:4527

Baquedano Y et al (2016) Novel heteroaryl selenocyanates and diselenides as potent antileishmanial agents. Antimicrob Agents Chemother 60(6):3802–3812

Baraqzeh A, Motazedian MH, Sattarahmady N, Morowvat MH, Rashidi S (2018) Preparation of meglumine antimonate loaded albumin nanoparticles and evaluation of its anti-leishmanial activity: an in vitro assay. J Parasit Dis 42(3):416–422

Barbosa CF et al (2014) Diphenyl diselenide and sodium selenite associated with chemotherapy in experimental toxoplasmosis: influence on oxidant/antioxidant biomarkers and cytokine modulation. Parasitology 141(13):1761–1768

Bartolini D et al (2017) Selenocompounds in cancer therapy: an overview. Adv Cancer Res 136:259–302

Bai K, Hong B, He J, Hong Z, Tan R (2017) Preparation and antioxidant properties of selenium nanoparticles-loaded chitosan microspheres. Int J Nanomed 12:4527
Beheshti N et al (2013) Efficacy of biogenic selenium nanoparticles against Leishmania major: in vitro and in vivo studies. J Trace Elem Med Biol 27(3):203–207

Bennett AP, Robinson MW (2021) Trematode proteomics: recent advances and future directions. Pathogens 10(3):348

Björnstedt M, Fernandes AP (2010) Selenium in the prevention of human cancers. EPMA Journal 1(3):389–395

Bonilla M, Krull E, Irgoin F, Salinas G, Comini MA (2016) Selenium compounds of African trypanosomes are dispensable for parasite survival in a mammalian host. Mol Biochem Parasitol 206(1–2):13–19

Brasil B, Chipolone J, Nascimento V (2020) Synthesis of new selenium-rich 1, 3-triazoles with potential activity against Trypanosoma cruzi. Chem Proc 2(1):22

Brindha J (2021) An overview on the therapeutics of neglected infectious diseases-leishmaniasis and chagas diseases. Front Chem 9:622286

Cabrera N, Mora JR, Márquez E, Flores-Morales V, Calle L, Cortés E (2021) QSPAR and molecular docking modelling of anti-leishmanial activities of organic selenium and tellurium compounds. SAR QSAR Environ Res 32(1):29–50

Cazarotto CJ et al (2018) Metaphylactic effect of minerals on immunological and antioxidant responses, weight gain and minimization of coccidiosis of newborn lambs. Res Vet Sci 121:46–52

Chao MN, Lorenzo-Ocampo MV, Szajnman SH, Docampo R, Rodriguez JB (2019) Further insights of selenium-containing analogues of WC-9 against Trypanosoma cruzi. Bioorg Med Chem 27(7):1350–1361

Chao MN et al (2017) Selenium-containing analogues of WC-9 are extremely potent inhibitors of Trypanosoma cruzi proliferation. Bioorg Med Chem 25(24):6435–6449

Chuai H et al (2021) Small molecule selenium-containing compounds: recent development and therapeutic applications. Eur J Med Chem 222:113621

Da Silva M, Silva-Jardim I, Thiemann O (2014) Biological implications of selenium and its role in trypanosomiasis treatment. Curr Med Chem 21(15):1772–1780

da Silva MTA et al (2020) Trypanosomatid selenophosphate synthetase structure, function and interaction with selenocysteine lyase. PLoS Negl Trop Dis 14(10):e0008091

Daetian N, Radfar M, Jahangard-Rafsanjani Z, Hadjibabaie M, Ghavamzadeh A (2014) Selenium supplementation in patients undergoing hematopoietic stem cell transplantation: effects on pro-inflammatory cytokines levels. DARU J Pharm Sci 22(1):51

de Freitas MRB, da Costa CMB, Pereira LM, do Prado Júnior JC, da Silva MTA et al (2020) Trypanosomatid selenophosphate synthetase homo-dimer and the Y strain of Trypanosoma cruzi with the Y strain of Trypanosoma cruzi-induced acute dilatation and reversion of Trypanosoma cruzi-induced acute dilatation and reversion of Trypanosoma cruzi-induced acute dilatation and reversion of Chagas disease: prevention of right ventricle chamber dilatation and reversion of Trypanosoma cruzi-induced acute and chronic cardiomyopathy in mice. Mem Inst Oswaldo Cruz 105(6):746–751

Dehnavi A, Ndao M, Reed SL (2013) Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes 4(1):66–71

Dharmalingam K et al (2021) Trace elements as immunoregulators in SARS-CoV-2 and other viral infections. Indian J Clin Biochem 36(4):416–426

Díaz M et al (2019) Synthesis and leishmanicidal activity of novel urea, thiourea, and selenourea derivatives of diselenides. Antimicrob Agents Chemother 63(5):e02200-e2218

Dkhil MA, Abdel-Baki AAS, Wunderlich F, Sies H, Al-Quraishy S (2014) Dietary selenium affects intestinal development of Eimeria papillata in mice. Parasitol Res 113(1):267–274

do Brasil PEAA et al (2014) Selenium treatment and chagasic cardiomyopathy (STCC): study protocol for a double-blind randomized controlled trial. Trials 15(1):388

Etxebeste-Mitxeltorena M et al (2020) New amides containing selenium as potent leishmanicidal agents targeting trypanothione reductase. Antimicrob Agents Chemother 65(1):e00524-e0260

Fernández-Rubio C et al (2015) Leishmanicidal activities of novel methylseleno-imidocarbamates. Antimicrob Agents Chemother 59(9):5705–5713

Fernández-Rubio C et al (2019) Leishmanicidal activity of isoselenocyanate derivatives. Antimicrob Agents Chemother 63(2):e00904-e918

Franco J, Sardi F, Szilágyi L, Kővér KE, Fehér K, Comini MA (2017) Diglycosyl diselenides alter redox homeostasis and glucose consumption of infective African trypanosomes. Int J Parasitol Drugs Drug Resist 7(3):303–313

Gardner TB, Hill DR (2001) Treatment of giardiasis. Clin Microbiol Rev 14(1):114–128

Garnica P et al (2020) Pre-clinical evidences of the antileishmanial effects of diselenides and selenocyanates. Bioorg Med Chem Lett 30(17):127371

Gomez RM, Solana ME, Levander OA (2002) Host selenium deficiency increases the severity of chronic inflammatory myopathy in Trypanosoma cruzi–inoculated mice. J Parasitol 88(3):541–547

Guarner J (2019) Chagas disease as example of a reemerging parasite. Semin Diagn Pathol 36(3):164–169

Guillén OM, Vindy C, Ohlmann T, Chavatte L (2019) Selenium, selenoproteins and viral infection. Nutrients 11(9):2101

Haldar K, Bhattacharjee S, Saha A (2018) Drug resistance in Plasmodium. Nat Rev Microbiol 16(3):156–170

Hallett RL et al (2004) Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother 48(10):3940–3943

Harihara R, Dharmaraj S (2020) Selenium and selenoproteins: its role in regulation of inflammation. Inflammopharmacology 28(3):667–695

Hassan IA, Wang S, Xu L, Yan R, Song X, Li X (2014) Immunoglobulin and cytokine changes induced following immunization with a DNA vaccine encoding Toxoplasma gondii selenium-dependent glutathione reductase protein. Exp Parasitol 146:1–10

Herbison R, Evans S, Doherty J-F, Algie M, Kleffmann T, Poulin R (2019) A molecular war: convergent and ontogenetic evidence for adaptive host manipulation in related parasites infecting divergent hosts. Proc Biol Sci 286(1915):20191827

Hilfier R, Rakotoambinina B (2020) Selenium and RNA virus interactions: potential implications for SARS-CoV-2 infection (COVID-19). Front Nutr 7:164

Hooper KJ et al (2014) Effect of selenium yeast supplementation on naturally acquired parasitic infection in ewes. Biol Trace Elem Res 161(3):308–317

Huang K, Yang S (2002) Inhibitory effect of selenium on Cryptosporidium parvum infection in vitro and in vivo. Biol Trace Elem Res 90(1):261–272

Huang Z, Rose AH, Hoffmann PR (2012) The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 16(7):705–745

Ikram M, Javed B, Raja NI, Z-U-R M (2021) Biomedical potential of plant-based selenium nanoparticles: a comprehensive review on therapeutic and mechanistic aspects. Int J Nanomed 16:249–268

Ilari A et al (2012) A gold-containing drug against parasitic polyamine transporters of African trypanosomes are dispensable for parasite survival in a mammalian host. Mol Biochem Parasitol 206(1–2):13–19

Jelicks LA, de Souza AP, Araújo-Jorge TC, Tanowitz HB (2011) Would selenium supplementation aid in therapy for Chagas disease? Trends Parasitol 27(3):102–105
Kalantar K et al (2021) Leishmanial apolipoprotein A1 expression: a possible strategy used by the parasite to evade the host’s immune response. Future Microbiol 16(8):607–613

Kang J-M, Ju H-L, Sohn W-M, Na B-K (2014) Characterization of biochemical properties of a selenium-independent glutathione peroxidase of Cryptosporidium parvum. Parasitology 141(4):570–578

Keyhani A et al (2020a) Prophylactic activity of biogenic selenium nanoparticles against chronic Toxoplasma gondii infection. Recent Pat Antinfect Drug Discov 15(1):75–84

Keyhani A et al (2020b) Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model. J Med Microbiol 69(1):104–110

Khan I, Saeed K, Khan I (2019) Nanoparticles: properties, applications and toxicities. Arab J Chem 12(7):908–931

Khatiwada S, Subedi A (2021) A mechanistic link between selenium and coronavirus disease 2019 (COVID-19). Curr Nutr Rep 10(2):125–136

Khosoo PA, Zhang Y, Yin H, Teng X, Li S (2019) Selenium deficiency affects immune function by influencing selenoprotein and cytokine expression in chicken spleen. Biol Trace Elem Res 187(2):506–516

Khurana A, Tekula S, Saifi MA, Venkatesh P, Godugu C (2019) Therapeutic applications of selenium nanoparticles. Biomed Pharmacother 111:802–812

Kieliszek M, Lipinski B (2020) Selenium supplementation in the prevention of cardiovascular infections (COVID-19). Med Hypotheses 143:30978

Kim HW et al (2012) Preventive effect of selenium on chronic bacterial prostatitis. J Infect Chemother 18(1):30–34

Kirtane AR, Verma M, Karandikar P, Furin J, Langer R, Traverso G (2021) Nanotechnology approaches for global infectious diseases. Nat Nanotechnol 16(4):369–384

Krishnan M, Ranganathan K, Maadhlu P, Thangavelu P, Kundan S, Arjunan N (2020) Leaf extract of Dillenia indica as a source of selenium nanoparticles with larvicidal and antimicrobial potential toward vector mosquitoes and pathogenic microbes. Coatings 10(7):626

Kudva AK, Shay AE, Prabhu KS (2015) Selenium and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 309(2):G71–G77

Kurokawa S, Berry MJ (2013) Selenium. Role of the essential metalloid in health. Metab Dis 13:499–534

Kuršvietienė I, Pakešienė L, Tuminaitė R, Šyšienė V, Brozmanová J, Letavayová L, Vlčková V, Brozmanová J (2006) Selenium: from cancer prevention to DNA damage. Toxicology 227(1–2):1–14

Letavayová L, Vlčková V, Brozmanová J (2006) Selenium: from cancer prevention to DNA damage. Toxicology 227(1–2):1–14

Lobanov AV et al (2006a) The plasmidium selenoproteome. Nucleic Acids Res 34(2):496–505

Lobanov AV, Gromer S, Salinas G, Gladyshev VN (2006b) Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res 34(14):4012–4024

López-Velez R, Batlle C, Jiménez C, Navarro M, Norman F, Pérez-Lobanov AV, Gromer S, Salinas G, Gladyshev VN (2006b) A highly efficient form of the selenocysteine-tRNA synthase. J Biol Chem 281(3):1203–1220

Martín-Elías R, Batlle C, Jiménez C, Navarro M, Norman F, Pérez-Lobanov AV, Gromer S, Salinas G, Gladyshev VN (2006b) Selenium derivatives as promising therapy for chagas disease: in vitro and in vivo studies. ACS Infect Dis 7(6):1727–1738

Martín-Elías R et al (2021b) Library of selenocysteine and diselenide derivatives as a new target for antichagasic compounds targeting Trypanosoma Cruzi Mitochondrion. Pharmaceuticals 14(5):419

Martin-Montes Á et al (2017) Library of seleno-compounds as novel agents against Leishmania species. Antimicrob Agents Chemother 61(6):e02546-e2616

Mesías AC, Garg NJ, Zago MP (2019) Redox balance keepers and possible cell functions managed by redox homeostasis in Trypanosoma cruzi. Front Cell Infect Microbiol 9:435

Mills RM (2020) Chagas disease: epidemiology and barriers to treatment. Am J Med 133(11):1262–1265

Mirotlicz A et al (2021) Selenium, Copper, Zinc Concentrations and Cu/Zn, Cu/Se Molar Ratios in the serum of patients with acute ischemic stroke in Northeastern Poland—a new insight into stroke pathophysiology. Nutrients 13(7):2139

Mosolygó T et al (2019) Selenocompounds as novel antibacterial agents and bacterial efflux pump inhibitors. Molecules 24(8):1487

Mostafavi M, Farajzadeh S, Sharifi I, Khazaeli P, Sharifi I (2019a) Leishmanial effects of amphotericin B in combination with selenium loaded on niosome against Leishmania tropica. J Parasit Dis 43(2):176–185

Mostafavi M et al (2019b) A novel niosomal combination of selenium coupled with glutamine against Leishmania tropica. Korean J Parasitol 57(1):1–8

Nafari A, Cheraghipour K, Sepahvand M, Shahrokhi G, Gabal E, Mahmoudvand H (2020) Nanoparticles: new agents toward treatment of leishmaniasis. Parasite Epidemiol Control 10:e00156

Nelson SM, Shay AE, James JL, Carlson BA, Urban JF, Prabhu KS (2016) Selenoprotein expression in macrophages is critical for optimal clearance of parasitic helmint Nippostrongylus brasiliensis. J Biol Chem 291(2):2787–2798

Notz Q et al (2021) Clinical significance of micronutrient supplementation in critically ill COVID-19 patients with severe ARDS. Nutrients 13(6):2113

Novoselov SV, Lobanov AV, Hua D, Kasaikina MV, Hatfield DL, Gladyshev VN (2007) A highly efficient form of the selenocysteine-tRNA synthase. J Biol Chem 282(10):9345–9353

Parsonage D et al (2016) X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. J Struct Biol 141(4):393–405

Machado VS et al (2016) Diphenyl diselenide supplementation in infected mice by Toxoplasma gondii: Protective effect on behavior, neutromodulation and oxidative stress caused by disease. Exp Parasitol 161:51–58

Mahmoudvand H, Shakiabae M, Tavakoli R, Jahanbakhsh S, Sharifi I (2014) In vitro study of leishmanicidal activity of biogenic selenium nanoparticles against Iranian isolate of sensitive and glucantime-resistant Leishmania tropica. Iran J Parasitol 9(4):452–460

Malekifard F, Tavassoli M, Vaziri K (2020) In vitro assessment of antiparasitic effect of selenium and copper nanoparticles on Giardia duodenalis Cyst. Iran J Parasitol 15(3):411–417

Manhas R, Gowri VS, Madhubala R (2016) Leishmanin donovani encodes a functional selenocysteinyl-tRNA synthase. J Biol Chem 291(3):1203–1220

Martín-Elías R et al (2021a) Selenium derivatives as promising therapy for chagas disease: in vitro and in vivo studies. ACS Infect Dis 7(6):1727–1738

Paranam MJ (2011) Immunomodulatory approaches to the treatment of infections. Infektološki Glasnik 31(1):15–27

Peeler JC, Weerapana E (2019) Chemical biology approaches to interrogate the selenoproteome. Acc Chem Res 52(10):2832–2840

Peña-Guerrero J, Fernández-Rubio C, Burguete-Mikeo A, El-Dirany R, García-Sosa AT, Ngewua P (2021) Discovery and validation of Lmj_04_BRCT domain, a novel therapeutic target: identification of candidate drugs for leishmaniasis. Int J Mol Sci 22(19):10493

Piacenza L, Trujillo M, Radi R (2019) Reactive species and pathogen antioxidant networks during phagocytosis. J Exp Med 216(3):501–516

Parasitology Research (2022) 121:49–62

61
Raina P, Kaur S (2012) Knockdown of LdMC1 and HSP70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in *Leishmania donovani*. J Biol Chem 359(1):135–149

Rashidi S, Kalantar K, Nguewa P, Hatam G (2020a) Leishmanial selenoproteins and the host immune system: towards new therapeutic strategies? Trans R Soc Trop Med Hyg 114(7):541–544

Rashidi S, Nguewa P, Mojahedi Z, Shahriari B, Kalantar K, Hatam G (2020b) Identification of immuno-reactive proteins in secretions of *Leishmania infantum* promastigotes: an immunoproteomic approach. East Mediterr Health J 26(12):1548–1555

Rivera MT et al (2002) Progressive Chagas’ cardiomyopathy is associated with low selenium levels. Am J Trop Med Hyg 66:706–712

Röseler A et al (2012) Insight into the selenoproteome of the malaria parasite *Plasmodium falciparum*. Antioxid Redox Signal 17(4):534–543

S Darvesh A, Bishayee A (2010) Selenium in the prevention and treatment of hepatocellular carcinoma. Anticancer Agents Med Chem 10(4):338–345

Santesmasses D, Mariotti M, GLadyshv VN (2020) Bioinformatics of selenoproteins. Antioxid Redox Signal 33(7):525–536

Shakibaie M, Ezzatkhah F, Gabal E, Badparva E, Jahanbakhsh S, Santesiassas D, Mariotti M, Guadyshv VN (2020) Bioinformatics of selenoproteins. Antioxid Redox Signal 33(7):525–536

Shalini S, Bansal MP (2007) Co-operative effect of glutathione depletion and selenium induced oxidative stress on API and NFκβ expression in testicular cells in vitro: insights to regulation of spermatogenesis. Biol Res 40(3):207–317

Sheneni V, Odiba V, Idih F (2018) Effect of administration of zinc and selenium on lipid peroxidation and endogenous antioxidant enzymes in *Trypanosoma brucei* infected albino rats. Open Access J Sci 2(6):383–387

Shojadoost B et al (2020) Supplemental dietary selenium enhances immune responses conferred by a vaccine against low pathogenicity *Avian influenza virus*. Vet Immunol Immunopathol 227:110089

Soffaei S et al (2014) Anti-leishmanial activities of selenium nanoparticles and selenium dioxide on *Leishmania infantum*. Comp Clin Path 23(1):15–20

Souza CC et al (2014) A potential link among antioxidant enzymes, histopathology and trace elements in canine visceral leishmaniasis. Int J Exp Pathol 95(4):260–270

Sowdaryapa R, Ramkumar G, Shivakumar M (2017) Green synthesis of selenium nanoparticles conjugated *Claussen dentata* plant leaf extract and their insecticidal potential against mosquito vectors. Artif Cells Nanomed Biotechnol 45(8):1490–1495

Sperk M et al (2020) Utility of proteomics in emerging and re-emerging infectious diseases caused by RNA viruses. J Proteome Res 19(11):4259–4274

Steinbrenner H, Al-Quraishy S, Dkhil MA, Wunderlich F, Sies H (2015) Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv Nutr 6(1):73–82

Suganya G, Karthi S, Shivakumar MS (2014) Larvicidal potential of silver nanoparticles synthesized from *Leucas aspera* leaf extracts against dengue vector Aedes aegypti. Parasitol Res 113(3):875–880

Sun Z, Liu C, Pan T, Yao H, Li S (2017) Selenium accelerates chicken dendritic cells differentiation and affects selenoproteins expression. Dev Comp Immunol 77:30–37

Taghipour A et al (2021) Leishmaniasis and trace element alterations: a systematic review. Biol Trace Elem Res 199(10):3918–3938

Turan E, Turksoy VA (2021) Selenium, zinc, and copper status in euthyroid nodular goiter: a cross-sectional study. Int J Prev Med 12(1):46

van de Crommenacker J, Richardson DS, Koltz AM, Hutchings K, Komdeur J (2012) Parasitic infection and oxidative status are associated and vary with breeding activity in the Seychelles warbler. Proc Biol Sci 279(1733):1466–1476

van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10(3):184–194

Volpato A et al (2018) A prolymphocytic protocol to stimulate the immune response also controls infectious disease and consequently, minimizes diarrhea in newborn heifers. Microb Pathog 121:262–268

Wang C, Wu Y, Qin J, Sun H, He H (2009) Induced susceptibility of host is associated with an impaired antioxidant system following infection with *Cryptosporidium parvum* in Se-deficient mice. PloS One 4(2):e4628

Xia H et al (2021) Effect of selenium and peroxynitrite on immune function of immature dendritic cells in humans. Med Sci Monit 27:e929004–e929011

Yazdi MH et al (2015) Th1 immune response induction by biogenic selenium nanoparticles in mice with breast cancer: preliminary vaccine model. Iran J Biotechnol 13(2):1–9

Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O (2020) Therapeutic nanoparticles and their targeted delivery applications. Molecules 25(9):2193

Zhang H-Y et al (2021) Association between fatality rate of COVID-19 and selenium deficiency in China. BMC Infect Dis 21(1):452

Zhang J, Saad R, Taylor EW, Rayman MP (2020) Selenium and selenoproteins in viral infection with potential relevance to COVID-19. Redox Biol 37:101715

Zhang J, Wang H, Yan X, Zhang L (2005) Comparison of short-term toxicity between Nano-Se and selenium in mice. Life Sci 76(10):1099–1109

Zhou X et al (2014) Increased levels of IL-6, IL-1β, and TNF-α in Khashin-Beck disease and rats induced by T-2 toxin and selenium deficiency. Rheumatol Int 34(7):995–1004

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.